Novaliq
Manufacturing · Germany · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Im Neuenheimer Feld 515, Heidelberg, Bad...Phone Number
+49 6221502590Website
www.novaliq.comRevenue
$22.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Novaliq
Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics, the worldwide first water-free technology. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases. Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Novaliq your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Novaliq, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Novaliq launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Novaliq is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Novaliq has new funding data
Congratulate Masked Content for being promoted to Masked Content at Novaliq
Earning: See what the market has to say on Novaliq recently announced quarterly report
Click to see if Novaliq had a recent Job posting/layoffs
Check if Novaliq has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Novaliq is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Novaliq is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Novaliq.
Novaliq financials insights
Gather financial insights about Novaliq, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Other Financing Round
$53M
Novaliq Tech Stack
A closer look at the technologies used by Novaliq
See more technologies
Novaliq News & Media
Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease
HEIDELBERG, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #CHMP--Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announces that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorisation in the European Union for Vevizye®, intended for the treatment of moderate to severe dry eye disease inNovaliq receives FDA nod for Vevye
Vevye (cyclosporine ophthalmic solution) 0.1% is used for the treatment of the signs and symptoms of dry eye disease.European Medicines Agency Accepts Novaliq’s Marketing Authorization Application for CyclASol® (ciclosporin ophthalmic solution) 0.1% for the Treatment of Dry Eye Disease
HEIDELBERG, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for CyclASol (ciclosporin ophthalmic solution) for regulatory review. CyclASol is an investigational new drug treatment for dry eye disease in patients not responding to tear substitutes. The Committee for Medicinal Products fHarrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
NASHVILLE, Tenn. & HEIDELBERG, Germany--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Novaliq GmbH, a German biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced an agreement under which Harrow will acquire the U.S. and Canadian commercial rights for VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary Eye
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Novaliq
Sign Up For FreeTo access detailed company insights
Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics, the worldwide first water-free technology. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases. Novaliq GmbH is headquartered in Heidelberg,... Read More
